ARTV vs ECL · rev $251.0K vs P/E 35, rev $4.01B
Artiva Biotherapeutics, Inc. Common Stock (ARTV) versus Ecolab Inc (ECL) — a side-by-side from cached financials, not a winner call.
Artiva Biotherapeutics, Inc. Common Stock (ARTV) is a biotechnology company listed on US.
Ecolab Inc (ECL) is a specialty chemicals company listed on US.
Latest reported ARTV revenue for 2024-12-31 was $251.0K. Net income was -$65.4M. Revenue was down 99.3% from 2023-12-31 to 2024-12-31. ARTV currently screens at market cap $37.3M.
Latest reported ECL revenue for 2024-12-31 was $4.01B. Net income was $2.13B. Revenue was up 0.2% from 2024-09-30 to 2024-12-31. ECL currently screens at market cap $72.05B and trailing P/E 34.6.
ARTV currently screens at market cap $37.3M. ECL currently screens at market cap $72.05B and trailing P/E 34.6.
Not investment advice. Open the ARTV and ECL stock pages for the full models.
Not investment advice.